Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi has arranged a ¥360 billion bridge loan from Sumitomo Mitsui Banking Corporation to finance its planned acquisition of the global rights to Tanabe Pharma’s amyotrophic lateral sclerosis treatments RADICAVA ORS and IV RADICAVA. The one-year, unsecured facility, agreed on May 24 with disbursement on May 27, underscores Shionogi’s drive to strengthen its rare disease portfolio and enhance its position in the neurodegenerative disease market.
The company intends to refinance the bridge loan with mid- to long-term funding by the May 26, 2027 repayment deadline, signaling a structured approach to managing the sizable investment. Shionogi expects only minimal impact on consolidated results for the fiscal year ending March 31, 2026, while the financial effects for fiscal 2027 are still under review, leaving investors attentive to how the acquisition and related financing will shape earnings and leverage metrics.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen4070.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a Japan-based pharmaceutical company focused on researching, developing, manufacturing, and marketing prescription drugs. The company has a growing presence in specialty and rare diseases, aiming to expand its global footprint through strategic acquisitions and partnerships in innovative therapies.
YTD Price Performance: 18.51%
Average Trading Volume: 2,959,296
Technical Sentiment Signal: Buy
Current Market Cap: Yen2961.4B
Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.